Page last updated: 2024-08-24

ibandronic acid and Jaw Diseases

ibandronic acid has been researched along with Jaw Diseases in 10 studies

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (40.00)29.6817
2010's5 (50.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Halling, F; Lux, C; Otto, M; Schlittenbauer, T; Ziebart, T1
Felsenberg, D; Gabbert, TI; Hoffmeister, B1
Aragon-Ching, JB; Arlen, PM; Chen, CC; Dahut, WL; Figg, WD; Guadagnini, JP; Gulley, JL; Latham, L; Ning, YM; Parnes, H; Wright, JJ1
Chandra, M; Go, AS; Gordon, NP; Hui, RL; Hutchinson, M; Lathon, PV; Lo, JC; Martin, D; McCloskey, CA; O'Ryan, FS; Sanchez, G; Selby, JV; Silver, P; Staffa, JA; Willy, M; Yang, J1
Andreadis, CG; Antoniades, K; Boukovinas, I; Katodritou, E; Kitikidou, K; Koloutsos, GE; Kyrgidis, A; Paraskevopoulos, P; Teleioudis, Z; Triaridis, S; Vahtsevanos, K; Verrou, E; Zervas, K1
Mattos, K; Migliorati, CA; Palazzolo, MJ1
Bauss, F; Drosse, I; Ehrenfeld, M; Opelz, C; Otto, S; Pautke, C; Schieker, M; Schwager, J; Westphal, I1
Pazianas, M1
Malden, NJ; Pai, AY1
Civitelli, R; Emkey, R; Strampel, W1

Reviews

2 review(s) available for ibandronic acid and Jaw Diseases

ArticleYear
Osteonecrosis of the jaw and the role of macrophages.
    Journal of the National Cancer Institute, 2011, Feb-02, Volume: 103, Issue:3

    Topics: Alendronate; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bone Density Conservation Agents; Denosumab; Diphosphonates; Etidronic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibandronic Acid; Imidazoles; Indoles; Jaw Diseases; Macrophages; Magnetic Resonance Imaging; Mevalonic Acid; Monocytes; Mouth Mucosa; Osteoclasts; Osteomyelitis; Osteonecrosis; Positron-Emission Tomography; Pyrroles; Radiography, Panoramic; RANK Ligand; Risedronic Acid; Risk Factors; Signal Transduction; Sunitinib; Tomography, X-Ray Computed; Vitamin D; Zoledronic Acid

2011
Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Drug safety, 2007, Volume: 30, Issue:9

    Topics: Acute-Phase Reaction; Administration, Oral; Alendronate; Bone Density Conservation Agents; Diphosphonates; Etidronic Acid; Female; Gastrointestinal Diseases; Humans; Ibandronic Acid; Injections, Intravenous; Jaw Diseases; Osteonecrosis; Osteoporosis, Postmenopausal; Renal Insufficiency; Risedronic Acid

2007

Trials

1 trial(s) available for ibandronic acid and Jaw Diseases

ArticleYear
Higher incidence of Osteonecrosis of the Jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents.
    Cancer investigation, 2009, Volume: 27, Issue:2

    Topics: Adult; Aged; Alendronate; Angiogenesis Inhibitors; Diphosphonates; Humans; Ibandronic Acid; Incidence; Jaw Diseases; Male; Middle Aged; Neoplasm Metastasis; Osteonecrosis; Prostatic Neoplasms

2009

Other Studies

7 other study(ies) available for ibandronic acid and Jaw Diseases

ArticleYear
Geranyl-geraniol addition affects potency of bisphosphonates-a comparison in vitro promising a therapeutic approach for bisphosphonate-associated osteonecrosis of the jaw and oral wound healing.
    Oral and maxillofacial surgery, 2022, Volume: 26, Issue:2

    Topics: Acyclic Monoterpenes; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; Clodronic Acid; Diphosphonates; Endothelial Cells; Humans; Ibandronic Acid; Jaw Diseases; Mouth Diseases; Osteonecrosis; Wound Healing; Zoledronic Acid

2022
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
    Journal of cancer research and clinical oncology, 2015, Volume: 141, Issue:4

    Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Female; Germany; Hematologic Neoplasms; Humans; Ibandronic Acid; Imidazoles; Jaw Diseases; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multiple Myeloma; Neoplasms; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Registries; Risk Factors; Sex Factors; Time Factors; Zoledronic Acid

2015
Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:2

    Topics: Administration, Oral; Aged; Alendronate; Bone Density Conservation Agents; California; Cross-Sectional Studies; Diphosphonates; Etidronic Acid; Female; Humans; Ibandronic Acid; Jaw Diseases; Male; Osteonecrosis; Prevalence; Risedronic Acid; Surveys and Questionnaires; Tooth Extraction

2010
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Nov-10, Volume: 27, Issue:32

    Topics: Adult; Aged; Aged, 80 and over; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Female; Greece; Humans; Ibandronic Acid; Imidazoles; Incidence; Jaw Diseases; Kaplan-Meier Estimate; Longitudinal Studies; Male; Middle Aged; Multiple Myeloma; Osteonecrosis; Pamidronate; Prostatic Neoplasms; Risk Factors; Zoledronic Acid

2009
How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care.
    Journal of the American Dental Association (1939), 2010, Volume: 141, Issue:5

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Alendronate; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Bone Neoplasms; Dental Care; Diphosphonates; Etidronic Acid; Female; Health Knowledge, Attitudes, Practice; Humans; Ibandronic Acid; Jaw Diseases; Male; Middle Aged; Osteonecrosis; Osteoporosis; Patient Education as Topic; Risedronic Acid; Risk Factors; Time Factors

2010
Osteonecrosis of the jaw: effect of bisphosphonate type, local concentration, and acidic milieu on the pathomechanism.
    Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons, 2010, Volume: 68, Issue:11

    Topics: Bone Density Conservation Agents; Cell Line; Cell Movement; Cell Proliferation; Cell Shape; Cell Survival; Clodronic Acid; Diphosphonates; Dose-Response Relationship, Drug; Fluorescent Dyes; Humans; Hydrogen-Ion Concentration; Ibandronic Acid; Imidazoles; Jaw Diseases; Mesenchymal Stem Cells; Osteonecrosis; Time Factors; Zoledronic Acid

2010
Oral bisphosphonate associated osteonecrosis of the jaws: three case reports.
    British dental journal, 2007, Jul-28, Volume: 203, Issue:2

    Topics: Administration, Oral; Aged; Alendronate; Anti-Bacterial Agents; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chlorhexidine; Clindamycin; Diphosphonates; Etidronic Acid; Facial Pain; Female; Humans; Ibandronic Acid; Jaw Diseases; Middle Aged; Oral Fistula; Osteonecrosis; Penicillin V; Risedronic Acid; Tooth Extraction

2007